Marshall Wace
FTH

Marshall Wace’s Faeth Therapeutics FTH Stock Holding History

Marshall Wace’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.16M Buy
206,508
+140,778
+214% +$3.26M ﹤0.01% 1357
2026
Q1 		$2.07M Buy
+65,730
New +$1.31M ﹤0.01% 1765

Other funds holding FTH

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Marshall Wace's FTH Position: Q2 2026 in Review

Marshall Wace increased its Faeth Therapeutics (FTH) stake by 214% in Q2 2026, buying an estimated $3.26M and bringing the position to 206,508 shares worth $5.16M. The position accounts for ﹤0.01% of the portfolio, ranked #1357.

Marshall Wace first reported a position in FTH in Q1 2026 and has held it in 2 quarters since. 45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

  • Marshall Wace held 206,508 shares of Faeth Therapeutics worth $5.16M as of Q2 2026.
  • Marshall Wace bought 140,778 Faeth Therapeutics shares in Q2 2026, an estimated $3.26M.
  • Faeth Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1357 holding.
  • Marshall Wace first reported a position in Faeth Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.